Desmoid Tumors: Module

CME

Treatment of Progressing Desmoid Tumors: Future Directions

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 15, 2023

Expiration: March 14, 2024

Bernd Kasper
Bernd Kasper, MD, PhD

Activity

Progress
1
Course Completed
References

  1. Riedel RF, Agulnik M. Evolving strategies for management of desmoid tumor. Cancer. 2022;128:3027-3040.
  2. Kasper B, Ströbel P, Hohenberger P. Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist. 2011;16:682-693.
  3. Hughes D, Kummar S, Lazar A. New, tolerable γ-secretase inhibitor takes desmoid down a notch. Clinical Cancer Research. 2015;21:7-9.
  4. Zhang Z, Shi J, Yang T, et al. Management of aggressive fibromatosis (review). Oncology Letters. 2021;21:1-11.
  5. The Desmoid Tumor Working Group. The management of desmoid tumors: a joint global consensus-based guideline approach for adult and paediatric patients. European Journal of Cancer. 2020;127:96-107.
  6. Skapek S, Ferguson W, Granowetter L, et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a pediatric oncology group phase II trial. Journal of Clinical Oncology. 2007;25:501-506.
  7. Palassini E, Frezza A, Marianai L, et al. Long-term efficacy of methotrexate plus vinblastine/vinorelbine in a large series of patients affected by desmoid-type fibromatosis. The Cancer Journal. 2017;23:86-91.
  8. Mir O, Rahal C, Rimareix F, et al. Efficacy of oral vinorelbine in advanced/progressive desmoid tumors: an updated retrospective study of 50 patients. Presented at: Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016. Abstract 11050.
  9. de Camargo VP, Keohan ML, D’Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer. 2010;116:2258-2265.
  10. Constantinidou A, Jones RL, Scurr M, et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. European Journal of Cancer. 2009;45:2930-2940.
  11. Constantinidou A, Jones RL, Scurr M, et al. Advanced aggressive fibromatosis: effective palliation with chemotherapy. Acta Oncologica. 2010;50:455-461.
  12. Pang A, Gouveia Macedo DV, Carbini M, et al. Pegylated liposomal doxorubicin (PLD) as an active treatment option for desmoid tumors (DT) patients. Presented at: Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016. Abstract 11032.
  13. Kasper B, Raut CP, Gronchi A. Desmoid tumors : to treat or not to treat, that is the question. Cancer. 2020;126:5213-5221.
  14. Gounder MM, Mahoney MR, Van Tine BA, et al. Sorafenib for advanced and refractory desmoid tumors. New England Journal of Medicine. 2018;379:2417-2428.
  15. Toulmonde M, Pulido M, Ray-Couard I, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumors (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncology. 2019;20:1263-1272.
  16. Shang H, Braggio D, Lee YJ, et al. Targeting the Notch pathway: a potential therapeutic approach for desmoid tumors. Cancer. 2015;121:4088-4096.
  17. Purow B. Notch inhibition as a promising new approach to cancer therapy. Advances in Experimental Medicine and Biology. 2012;727:305-319.
  18. Kasper B, Ratan R, Alcindor T, et al. DeFi: a phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT). Presented at: Annual Congress for the European Society for Medical Oncology; September 9-13, 2022. Abstract LBA2.
  19. Gounder MM, Jones RL, Chugh R, et al. Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT). Presented at: Annual Congress for the European Society for Medical Oncology; September 9-13, 2022. Abstract 1488M0.